Quantcast

Latest Bare-metal stent Stories

2011-04-05 07:30:00

NATICK, Mass., April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA(TM) Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA). Enrollment is planned for up to 300 patients at 50 sites in...

2011-03-29 07:30:00

NATICK, Mass., March 29, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans. "Twelve-month results from the PLATINUM Workhorse clinical trial will provide important data on our next-generation PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our market-leading...

2011-03-07 07:30:00

NATICK, Mass., March 7, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology. It incorporates Boston Scientific's unique platinum chromium (PtCr) alloy designed specifically for coronary stenting and is intended to provide interventional cardiologists with a bare-metal stent with improved acute performance in...

2011-02-17 07:00:00

DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's...

2011-01-24 07:30:00

NATICK, Mass., Jan. 24, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY(TM) Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element(TM) Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery...

2010-12-02 07:00:00

HONG KONG, Dec. 2, 2010 /PRNewswire/ -- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis. The cumulative rate of the study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year follow-up, was 12.4% in patients treated with a Genous Stent, a 30%...

2010-11-29 06:00:00

DURHAM, N.C., Nov. 29, 2010 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent(TM) Drug Eluting Coronary Stent System (MiStent DES). DESSOLVE I is a prospective, open-label,...

2010-11-03 08:31:00

TORONTO, Nov. 3, 2010 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable. Although drug-coated balloons lack extensive clinical data comparing their efficacy against other technologies, such as...

2010-10-05 10:54:00

TORONTO, Oct. 5 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the Canadian interventional cardiology device market is a highly competitive and dynamic market, with a small number of large competitors fighting for market share in this extremely profitable area. As of 2010, the drug-eluting stent segment represented a $55 million market -- the most lucrative of the interventional cardiology device markets....

2010-09-25 10:34:00

NATICK, Mass., Sept. 25 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and The Medicines Company (Nasdaq: MDCO), is designed to determine the safety and efficacy of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.